Abstract: This invention provides a process for reducing the amount of soluble halide in a solution comprising a liquid organic medium, at least one viscosity reducing agent, at least one dihydrocarbylmagnesium compound, and an initial amount of soluble halide. The process comprises mixing at least one alkali metal with the solution at a mole ratio of alkali metal to magnesium of less than about 1:2.5, thereby forming precipitated soluble halides. Also provided by this invention is a process for reducing the amount of soluble halide in a slurry comprising a liquid organic medium, at least one viscosity reducing agent, at least one dihydrocarbylmagnesium compound, solids from the formation of said dihydrocarbylmagnesium compound, and an initial amount of soluble halide. This process comprises mixing at least one alkali metal with the slurry at a mole ratio of alkali metal to magnesium of less than about 1:1.25, thereby forming precipitated soluble halides.

Abstract: The present invention relates to stabilized statin particles and process for preparation thereof.

Abstract: This invention provides a process for producing a protic ammonium tetrakis(Faryl)borate. The process comprises mixing together (a) at least one alkali metal tetrakis(Faryl)borate, at least one magnesium tetrakis(Faryl)borate, at least one halo-magnesium tetrakis(Faryl)borate, or a mixture of two or more of the foregoing, (b) at least one amine, and (c) one or more liquid dihydrocarbyl ethers, one or more liquid hydrocarbons, one or more liquid halogenated hydrocarbons, or a mixture of two or more of the foregoing, to form a solution or slurry in a liquid organic medium. At least one protic acid is mixed together with at least a portion of the solution or slurry formed in i), such that a protic ammonium tetrakis(Faryl)borate is formed. The amine has the formula R3N, in which each R is independently a hydrocarbyl group containing up to about thirty carbon atoms.

Abstract: The present invention relates to stable oral compositions of azithromycin monohydrate with reduced bitterness, processes for making these compositions, and methods of using these compositions for the treatment of microbial infections. The stable oral compositions of azithromycin include an azithromycin premix, at least one pharmaceutically accepted excipient, and, optionally, at least one taste-masking agent. The azithromycin premix includes azithromycin monohydrate and at least one additive.

Abstract: The technical field of the present invention relates to uncoated, taste masked sumatriptan tablets for oral administration and processes for their preparation. It also relates to wax polished sumatriptan tablets and processes for their preparation.

Abstract: The technical field of the invention relates to pharmaceutical compositions of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir) that are stable and contain more than 1% water content. One pharmaceutical composition includes ganciclovir having more than about 1% water content, and one or more pharmaceutically acceptable excipients. The ganciclovir retains at least about 97% of its initial purity after one month, at least about 96% of its initial purity after two months, and at least about 95% of its initial purity after three months when stored at 40° C. and 75% RH. In particular, the water content may be between about 2% and about 6%.

Abstract: The present invention relates to controlled release pharmaceutical compositions of carbidopa and levodopa that include a combination of different molecular weight cellulose ethers and in particular, hydroxypropyl cellulose ether.

Abstract: The technical field of the present invention relates to the selection of lubricants to provide a storage stable tablet of fosinopril, alone or in combination with a diuretic, as well as processes of preparation of the stable tablets. In particular, the lubricants are a combination of colloidal silicon dioxide and talc.

Abstract: The invention provides stable pharmaceutical compositions comprising ACE inhibitor(s) and other pharmaceutically active substances which are susceptible to degradation, as well as processes for the preparation thereof, and methods of treatment involving administration of such compositions.

Abstract: The present invention relates to pharmaceutical compositions of quinapril and processes for their preparation. One pharmaceutical composition includes a therapeutically effective amount of quinapril or an acid addition salt thereof and between about 15% w/w to about 40% w/w of an alkaline substance.